Original Article

Evaluation of the in vitro efficacy of antimicrobials against Enterobacterales with multiple carbapenemase enzymes

Abstract

Background and Objectives: High-dose of carbapenems and combination therapies with new β-lactam/β-lactamase inhibitors and polymyxin B/tigecycline have been considered for treatment of carbapenem resistant Enterobacterales infection. The research was conducted to evaluate the in vitro potency of aminoglycosides, ceftazidime/avibactam/aztreonam and tigecycline against isolates of Enterobacteriaceae with multiple carbapenemase enzymes.
Materials and Methods: 42 genotypically confirmed carbapenem resistant Enterobacterales (twenty-nine NDM producers, nine NDM and OXA-48 producers, three NDM and VIM producers and one NDM combined with VIM and OXA 48 producer) were included. Minimum inhibitory concentration for carbapenems, aminoglycosides and tigecycline was determined by Vitek 2. Ceftazidime/avibactam/aztreonam synergy was observed by disk diffusion methodology.
Results: The in vitro efficacy of aminoglycosides was observed against Escherichia coli (E. coli) isolates with NDM and VIM genes. Low tigecycline susceptibility was observed among Klebsiella pneumoniae (K. pneumoniae) isolates with NDM and OXA-48 genes. Ceftazidime -avibactam/aztreonam combination displayed good in vitro activity against dual carbapenemase producers of E. coli isolates (NDM with OXA-48 and NDM with VIM genes) and Klebsiella pneumoniae (combination of NDM, VIM and OXA-48 genes).
Conclusion: Ceftazidime/avibactam/aztreonam, aminoglycosides and tigecycline displayed in vitro activity against dual carbapenemase producers of E. coli and K. pneumoniae.

1. Wu W, Feng Y, Tang G, Qiao F, McNally A, Zong Z. NDM Metallo-β-Lactamases and their bacterial producers in health care settings. Clin Microbiol Rev 2019; 32(2): e00115-18.
2. Tiseo G, Suardi LR, Leonildi A, Giordano C, Barnini S, Falcone M. Meropenem/vaborbactam plus aztreonam for the treatment of New Delhi metallo-β-lactamase-producing Klebsiella pneumoniae infections. J Antimicrob Chemother 2023; 78: 2377-2379.
3. Bianco G, Boattini M, Comini S, Casale R, Iannaccone M, Cavallo R, et al. Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era. Eur J Clin Microbiol Infect Dis 2022; 41: 573-580.
4. Papp-Wallace KM. The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections. Expert Opin Pharmacother 2019; 20: 2169-2184.
5. Lee YR, Baker NT. Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae. Eur J Clin Microbiol Infect Dis 2018; 37: 1411-1419.
6. Vena A, Giacobbe DR, Castaldo N, Cattelan A, Mussini C, Luzzati R, et al. Clinical experience with Ceftazidime-Avibactam for the treatment of infections due to multidrug-resistant Gram-Negative bacteria other than carbapenem-resistant Enterobacterales. Antibiotics (Basel) 2020; 9: 71.
7. Sheu C-C, Chang Y-T, Lin S-Y, Chen Y-H, Hsueh P-R. Infections caused by carbapenem-resistant Enterobacteriaceae: an update on Therapeutic options. Front Microbiol 2019; 10: 80.
8. Teo JQ, Fauzi N, Ho JJ, Tan SH, Lee SJ, Lim TP, et al. In vitro bactericidal activities of combination antibiotic therapies against Carbapenem-Resistant Klebsiella pneumoniae with different Carbapenemases and Sequence types. Front Microbiol 2021; 12: 779988.
9. Clinical and Laboratory Standards Institute (CLSI) (2021). Performance Standards for antimicrobial susceptibility testing. 31st ed. CLSI supplement M100. Clinical and Laboratory Standards Institute, USA. https://www.treata.academy/wp-content/uploads/2021/03/CLSI-31-2021.pdf
10. Borgohain A, Rangaiah A, Rangappa KG. In Vitro Effect of Ceftazidime-Avibactam by synergy testing with Aztreonam using Disc E Strip Method - Contribution of Promising Combination in the Era of antibiotic resistance. Int J Pharm Clin Res 2024; 16: 1249-1255.
11. Cismaru IM, Vacaroiu MC, Soium E, Holban T, Radu AM, Melinte V, et al. Synergistic Combination of Aztreonam and Ceftazidime-Avibactam-A Promising Defense Strategy against OXA-48 + NDM Klebsiella pneumoniae in Romania. Antibiotics (Basel) 2024; 13: 550.
12. Shaw E, Rombauts A, Tubau F, Padulles A, Camara J, Lozano T, et al. Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection. J Antimicrob Chemother 2018; 73: 1104-1106.
13. Niu S, Wei J, Zou C, Chavda KD, Lv J, Zhang H, et al. In vitro selection of aztreonam/avibactam resistance in dual-carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother 2020; 75: 559-565.
14. Gaibani P, Lewis RE, Volpe SL, Giannella M, Campoli C, Landini MP, et al. In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates. Int J Infect Dis 2017; 65: 1-3.
15. Wu Y, Yu W, Chu X, Zhang J, Jia P, Liu X, et al . Effect of ceftazidime-avibactam combined with different antimicrobials against carbapenem-resistant Klebsiella pneumoniae. Microbiol Spectr 2024; 12(6): e0010724.
16. Mikhail S, Singh NB, Kebriaei R, Rice SA, Stamper KC, Castanheira M, et al. Evaluation of the synergy of ceftazidime-avibactam in combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against well-characterized multidrug-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2019; 63(8): e00779-19.
17. Wang F, Zhou Q, Yang X, Bai Y, Cui J. Evaluation of ceftazidime/avibactam alone and in combination with amikacin, colistin and tigecycline against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae by in vitro time-kill experiment. PLoS One 2021; 16(10): e0258426.
18. Rogers TM, Kline EG, Griffith MP, Jones CE, Rubio AM, Squires KM, et al. Mutations in ompK36 differentially impact in vitro synergy of meropenem/vaborbactam and ceftazidime/avibactam in combination with other antibiotics against KPC-producing Klebsiella pneumoniae. JAC Antimicrob Resist 2023; 5: dlad113.
Files
IssueVol 17 No 3 (2025) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijm.v17i3.18821
Keywords
Enterobacterales Dual carbapenemase In vitro activity Metallobetalactamases
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Rajan R, Sasikala G. Evaluation of the in vitro efficacy of antimicrobials against Enterobacterales with multiple carbapenemase enzymes. Iran J Microbiol. 2025;17(3):390-396.